Forefront Analytics LLC Buys 26 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forefront Analytics LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 319 shares of the biopharmaceutical company’s stock after buying an additional 26 shares during the period. Forefront Analytics LLC’s holdings in Regeneron Pharmaceuticals were worth $280,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Groupama Asset Managment purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $59,190,000. Point72 Hong Kong Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $7,188,000. Avidity Partners Management LP grew its holdings in shares of Regeneron Pharmaceuticals by 17.2% during the 4th quarter. Avidity Partners Management LP now owns 68,000 shares of the biopharmaceutical company’s stock worth $59,724,000 after acquiring an additional 10,000 shares during the period. Caxton Associates LP purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $8,783,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $1,360,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $1.12 during trading on Thursday, reaching $1,026.55. 315,348 shares of the company’s stock traded hands, compared to its average volume of 470,660. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $1,030.82. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm has a market cap of $113.12 billion, a PE ratio of 30.20, a P/E/G ratio of 2.07 and a beta of 0.13. The company has a 50-day simple moving average of $952.62 and a 200-day simple moving average of $932.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on REGN shares. Royal Bank of Canada upped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Bank of America boosted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $991.18.

Insiders Place Their Bets

In other news, CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the sale, the chief executive officer now owns 55,134 shares of the company’s stock, valued at approximately $55,984,717.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the completion of the sale, the chief executive officer now owns 55,134 shares of the company’s stock, valued at approximately $55,984,717.62. The disclosure for this sale can be found here. Insiders have sold 59,680 shares of company stock valued at $58,818,382 in the last ninety days. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.